Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Analgesic agents under development at Meiji Seika

Aug. 23, 2000

In vivo results presented for PARP inhibitor GPI-6150

Aug. 23, 2000

Highly selective m4 muscarinic receptor antagonist described

Aug. 23, 2000

Novel compounds useful for neurological disorders claimed by AstraZeneca

Aug. 22, 2000

Elan and Biogen establish Antegren collaboration agreement

Aug. 22, 2000

New series of PARP inhibitors claimed by Guilford

Aug. 22, 2000

Syntheses and SAR presented for DuPont Pharmaceuticals' CRF receptor antagonists

Aug. 22, 2000

deCODE Genetics and Roche reach milestone in Alzheimer's research

Aug. 21, 2000

Novel series of group II mGlu receptor agonists described at ACS meeting

Aug. 21, 2000

DHEA evaluated for depression, AD and adrenal insufficiency

Aug. 18, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...